Bleakley Financial Group LLC Has $3.11 Million Stock Position in CVS Health Corporation $CVS

Bleakley Financial Group LLC lowered its stake in CVS Health Corporation (NYSE:CVS) by 39.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 39,218 shares of the pharmacy operator’s stock after selling 25,268 shares during the quarter. Bleakley Financial Group LLC’s holdings in CVS Health were worth $3,112,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in CVS. Sei Investments Co. increased its stake in shares of CVS Health by 17.4% in the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after purchasing an additional 134,535 shares during the period. The Manufacturers Life Insurance Company increased its stake in CVS Health by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after acquiring an additional 13,329 shares during the period. Treasurer of the State of North Carolina boosted its holdings in CVS Health by 1.3% during the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after purchasing an additional 7,588 shares in the last quarter. HUB Investment Partners LLC boosted its holdings in CVS Health by 25.0% during the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after purchasing an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in CVS Health by 8.0% during the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after purchasing an additional 119,439 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CVS. UBS Group boosted their target price on CVS Health from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. TD Cowen upped their price objective on CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. DA Davidson upped their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, JPMorgan Chase & Co. upped their price objective on shares of CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $98.88.

CVS Health Trading Up 1.4%

CVS Health stock opened at $92.02 on Thursday. CVS Health Corporation has a one year low of $58.50 and a one year high of $98.43. The company has a market cap of $117.41 billion, a price-to-earnings ratio of 40.54, a P/E/G ratio of 0.89 and a beta of 0.60. The firm has a 50-day moving average of $81.35 and a 200-day moving average of $79.37. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same period last year, the business posted $2.25 EPS. CVS Health’s revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.9%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last quarter. 0.85% of the stock is currently owned by company insiders.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Barclays raised its price target on CVS Health to $106 from $101 and maintained an overweight rating, signaling improved Wall Street confidence in the stock’s upside. Barclays price target raise
• Positive Sentiment: Aetna said its second-generation Claims Assist Manager, an AI-powered claims platform, has cut claims processing time by more than 20% while improving payment accuracy, a potential margin and efficiency tailwind for CVS Health. Aetna AI claims update
• Positive Sentiment: MinuteClinic and Hartford HealthCare expanded primary care access across Connecticut, adding another growth-oriented partnership that could help CVS broaden patient access and utilization. MinuteClinic Hartford HealthCare expansion
• Positive Sentiment: Aetna Better Health of Missouri announced a $175,000 community investment to address food insecurity and safety/wellness supports, reinforcing CVS Health’s Medicaid/community-health positioning. Aetna Missouri community investment
• Neutral Sentiment: CVS Health is also drawing attention for broader analyst commentary, but the article provided did not include a clear new catalyst beyond market discussion. Analyst commentary on CVS Health
• Negative Sentiment: CVS sued Tennessee over a new PBM-pharmacy ownership law, arguing it unlawfully targets out-of-state companies and could force the company to shut pharmacies in the state, creating regulatory and earnings risk. CVS Tennessee lawsuit

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.